Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag for thrombocytopenia in lower-risk myelodysplastic syndromes
2012-004886-42Phase 2Terminated
- Sponsor
- University of Crete
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eltrombopag in myelodysplastic syndrome (MDS) and Thrombocytopenia, sponsored by University of Crete. Primary endpoints: Platelet count response and Safety and tolerability. Started Mar 2013; status: terminated.
02
Drugs
eltrombopag
03
Conditions
myelodysplastic syndrome (MDS)Thrombocytopenia
Beyond the preview
Go deeper on 2012-004886-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004886-42.